Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...

In this article, we are going to take a look at where aTyr Pharma, Inc. (NASDAQ:ATYR) stands against other best multibagger stocks. November has been an eventful month so far for the market as the ...

aTyr Pharma, Inc. announced the appointment of Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, currently the Chief Commercial Officer at Neurocrine Biosciences ...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on December 27.Stay Ahead of the ...

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1.

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including ...